Left unchecked, many chronic inflammatory and autoimmune diseases lead to fibrosis, which can ultimately irreversibly compromise tissue and organ function. A key question for therapeutic discovery and development is whether it is preferable to target i…
Malignant melanoma is characterized by high heterogeneity, aggressive metastatic potential, and a profoundly immunosuppressive “cold” tumor microenvironment, contributing to broad therapeutic resistance and suboptimal responses to immunotherapy. Conven…
Lumbar disc herniation (LDH) is a prevalent condition driven by inflammation, which mediates both radicular pain and spontaneous resorption of herniated material. Traditional anti-inflammatory therapies alleviate pain but may impede disc regression. We…
We focused on a paper titled “Radiation with immunotherapy may be a double-edged sword—how can we learn from recent negative clinical trials?”, which was published in JAMA Oncology recently. Herein, we initially provided three complementary viewpoints …
In the last decades, immunotherapy has revolutionized cancer treatment. Despite its success, a significant number of patients fail to respond, and the underlying causes of ineffectiveness remain poorly understood. Factors such as nutritional status and…
Programmed death-1 (PD-1) and its ligand PD-L1 inhibitors have become pivotal agents in cancer immunotherapy, demonstrating significant efficacy across multiple malignancies. However, beyond regulating T cell activation, the PD-1/PD-L1 axis also exerts…
Malignant melanoma brain metastases (MBM) represent one of the deadliest complications of melanoma, with an incidence rate of 7.3%. Among patients with acral and mucosal melanoma, the cumulative 5-year incidence can reach 19.5%, accompanied by poor pro…
Immune-mediated inflammatory diseases (IMIDs) are incurable pathologies with an increased prevalence. Whereas different risk factors for IMIDs have been identified, such as microbial dysbiosis, diet, Epstein-Barr virus infection, the exact cause of mos…
Type 1 diabetes (T1D) is an autoimmune disease characterized by the progressive destruction of pancreatic β-cells, leading to insulin deficiency and chronic hyperglycemia. While immune-mediated mechanisms of β-cell destruction are well-recognized, emer…
Immunotherapy has revolutionized the treatment landscape for many cancers, including some B- cell lymphomas. Immune checkpoint blockade, CAR-T cells and bispecific antibodies have shown promise for the treatment of Richter Transformation (RT) but have …
